CVS caremark™ {{PANUMCODE}}

Zejula

Prior Authorization Request

CVS Caremark administers the prescription benefit plan for the patient identified. This patient's benefit plan requires prior authorization for certain medications in order for the drug to be covered. To make an appropriate determination, providing the most accurate diagnosis for the use of the prescribed medication is necessary. **Please respond below and fax this form to CVS Caremark toll-free at 1-866-249-6155**. If you have questions regarding the prior authorization, please contact CVS Caremark at **1-866-814-5506.** For inquiries or questions related to the patient's eligibility, drug copay or medication delivery; please contact the Specialty Customer Care Team: CaremarkConnect® 1-800-237-2767.

The recipient of this fax may make a request to opt-out of receiving telemarketing fax transmissions from CVS Caremark. There are numerous ways you may opt-out: The recipient may call the toll-free number at 877-265-2711, at any time, 24 hours a day/7 days a week. The recipient may also send an opt-out request via email to do_not_call@cvscaremark.com. An opt out request is only valid if it (1) identifies the number to which the request relates, and (2) if the person/entity making the request does not, subsequent to the request, provide express invitation or permission to CVS Caremark to send facsimile advertisements to such person/entity at that particular number. CVS Caremark is required by law to honor an opt-out request within thirty days of receipt.

Patient's Name: {{MEMFIRST}} {{MEMLAST}} **Date**: {{TODAY}}
Patient's ID: {{MEMBERID}} **Patient's Date of Birth:** {{MEMBERDOB}}
Physician's Name: {{PHYFIRST}} {{PHYLAST}}
Specialty: _____, NPI#: _____
Physician Office Telephone: {{PHYSICIANPHONE}} **Physician Office Fax:** {{PHYSICIANFAX}}
Request Initiated For: {{DRUGNAME}}

1. What is the diagnosis?
   - ❑ Epithelial ovarian, fallopian tube, or primary peritoneal cancer
   - ❑ Uterine leiomyosarcoma
   - ❑ Other _____
2. What is the ICD-10 code? _____
3. Is the patient currently receiving treatment with the requested medication?
   ❑ Yes ❑ No *If No, skip to #5.*
4. Is there evidence of disease progression or unacceptable toxicity while on the current regimen?
   ❑ Yes ❑ No *No further questions.*
5. Will the requested medication be used as a single agent? ❑ Yes ❑ No
6. What clinical setting will the requested medication be used?
   - ❑ Advanced (Stage II-IV) disease
   - ❑ Advanced disease
   - ❑ Recurrent disease
   - ❑ Metastatic disease
   - ❑ Inoperable disease
   - ❑ Other _____

Complete the following section based on the patient's diagnosis, if applicable.

Section A: Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

7. Is the requested medication being used as maintenance treatment? ❑ Yes ❑ No
8. Is the patient in a complete or partial response to platinum-based (e.g., cisplatin, carboplatin) chemotherapy?
   ❑ Yes ❑ No
9. Does the patient have a deleterious or suspected deleterious germline BRCA mutation? ***ACTION REQUIRED: If Yes, attach chart note(s) or test results confirming BRCA mutation status.*** ❑ Yes ❑ No ❑ Unknown

Send completed form to: Case Review Unit CVS Caremark Prior Authorization Fax: 1-866-249-6155

Section B: Uterine Leiomyosarcoma

10. Does the patient have BRCA2-altered uterine leiomyosarcoma? ***ACTION REQUIRED: If Yes, attach chart note(s) or test results confirming BRCA2 mutation status.*** ❑ Yes ❑ No ❑ Unknown

11. What is the place in therapy in which the requested medication will be used?
    ❑ First-line treatment
    ❑ Subsequent treatment

I attest that this information is accurate and true, and that documentation supporting this information is available for review if requested by CVS Caremark or the benefit plan sponsor.

X_____

Prescriber or Authorized Signature **Date (mm/dd/yy)**

Send completed form to: Case Review Unit CVS Caremark Prior Authorization Fax: 1-866-249-6155